ProCE Banner Activity

FAVOUR: Phase Ib Study of Furmonertinib in EGFR Exon 20 Insertion–Positive Locally Advanced or Metastatic NSCLC

Conference Coverage

Current update of the phase Ib FAVOUR trial showed promising efficacy and safety with the third-generation, selective EGFR TKI furmonertinib in treatment-naive and previously treated patients with EGFR ex20ins–positive locally advanced or metastatic NSCLC.

Released: September 14, 2023


Provided by

Provided by Clinical Care Options. LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc